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Introduction
The word “incretin” was coined by the Belgian physiologist La 
Barre1 to describe gut hormones that stimulated pancreatic 
hormone secretion and proposed it in diabetes treatment. In 
1993, Nauck et  al2 demonstrated that an infusion of exoge-
nous GLP-1 agonists normalized fasting plasma glucose in 
poorly-controlled type 2 diabetic patients. Thereafter it was 
confirmed that GLP-1 is also able to inhibit the secretion of 
pancreatic glucagon, providing yet another mechanism to 
abolish the hyperglycemia in diabetic patients.3 Additional 
effects involving satiety slowed gastric emptying, and weight 
loss has made it a good option used by many doctors.4 Recently, 
the American Diabetes Association (ADA) treatment algo-
rithm recommended GLP-1 receptor agonists for the diabetic 
patients who develop atherosclerotic cardiovascular disease 
(ASCVD) or chronic kidney disease (CKD) after uncon-
trolled metformin line of treatment.5-9 However, GLP-1 
receptor agonists have been proposed to be associated with 
many adverse effects, including cancer, systematic complica-
tions, and hypoglycemia under combined treatments.10 In 
1998, GLP-1 receptor agonists were suggested to be associ-
ated with hypoglycemic symptoms in certain individuals, 
which proposes the non-glucose-dependent action.11 In addi-
tion, other factors have been assumed to be associated with the 
action of GLP-1 receptor agonists (Figure 1).12
The current review aims to describe and discuss up-to-date 
literature data related to GLP-1 receptor agonists’ effect on the 
development of hypoglycemia and some other adverse effects 
in type 2 diabetic patients (Figure 2).
Definitions of hypoglycemia in diabetes
Hypoglycemia or low blood sugar is defined by the ADA as all 
episodes of an abnormally low plasma glucose concentration 
that expose the individual to potential harm, they did not 
assign a single threshold that defines as glycemic thresholds for 
symptoms differ between individuals, However, they did iden-
tify an alert value which when present should alert the patient 
to the possibility of the potential clinically evident harm asso-
ciated with hypoglycemia. This alert value can be used to 
prompt patients to self-treat (though not always) with oral car-
bohydrate ingestion, repeat the test or avoid driving and elec-
tive exercise until the blood sugar returns to normal.13
In this review we cite many studies each reporting hypoglyce-
mia in different ways, below is the summary of those ways/values:
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STUDy How HyPoGlyCEMiA wAS DEFiNED iN THE 
STUDy
Edwards et al11 Fall in fasting blood glucose below the normal 
range (4.22–6.11 mmol)
lerche et al12 An abnormally low 3-h oral glucose tolerance 
test (oGTT) result
Nauck et al14 Symptoms and plasma glucose <3.1 mmol/l
Marre et al15 Plasma glucose levels <3.1 mmol/l
Nauck et al16 Symptoms of hypoglycemia were rated on a 
visual analog scale ranging from 0 to 10
(Continued)
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Methods
The search was limited to the English language, and we con-
ducted an internet search in Google Scholar, PubMed, and 
Scopus databases using the following keywords: Glucagon-like 
protein, glucagon-like peptide receptor agonist, type 2 diabetes 
mellitus, hypoglycemia.
Molecular physiology of GLP-1
Stimulation of the pancreatic β-cells to secrete insulin as an 
incretin hormone is the primary physiological feature of GLP-
1. GLP-1 also has additional non-incretin functions, including 
glucagon secretion repression, gastric motility inhibition, and 
satiety enhancement. Through sequencing the peptides iso-
lated from gut extraction, naturally occurring GLP-1 was 
identified in the late 1980s, and subsequent studies showed 
that GLP1(7-37) and GLP-1 (7-36) amide are the natural 
bioactive forms of GLP-1. GLP-1, like GIP and GLP-2, has a 
closely preserved alanine structure at position 9, which makes 
these peptides suitable substrates for dipeptidyl peptidase 4.25,26
Glucagon is processed by prohormone convertase 2 (PC2) 
and released from alpha cells, while GLP-1 and GLP-2 are 
released by PC1/3 from the intestinal L cells as bioactive hor-
mones. As a result, after the absorption of nutrients, GLP-1 
and GLP-2 are co-released in a 1:1 ratio, mainly after meals 
rich in carbohydrates and lipids. In vivo, owing to DPP-4 
intervention, GLP-1’s biological half-life is just 1 to 2 minutes. 
There are several GLP-1 secretagogues, secreted by nutrients 
such as lipids and carbohydrates. Also, some hormones also 
control GLP-1 secretion, such as cholecystokinin (CCK), GIP, 
somatostatin, and various neuromediators.27,28
The human receptor for GLP-1 contains a broad hydro-
philic extracellular and 7 hydrophobic transmembrane 
domains. There are 3 possible N-linked glycosylation sites for 
the GLP-1 receptor protein where glycosylation can modulate 
receptor activity.29
The GLP-1 receptor is functionally linked via the Gs pro-
tein signaling cascade to adenyl cyclase (AC). The cAMP is 
formed and stimulates protein kinase A (PKA) by activation of 
adenylyl cyclase. Ligand receptor activation also raises intra-
cytoplasmic Ca2+ concentration, which is believed to be 
accomplished both by Na-dependent extracellular Ca2+ 
uptake and by Ca2+ release from intracellular Ca2+ stores. 
Increased cytosolic Ca2+ in combination with activated PKA 
promotes insulin translocation and exocytosis containing secre-
tory granules.30
GLP1 receptor agonists physiology and 
hypoglycemia
The response to oral glucose stimulates a higher and more sus-
tained release of insulin than intravenous (IV) glucose, and 
that this is attributed to the effect of the 2 incretin hormones, 
glucose-dependent insulinotropic polypeptide (GIP), and 
glucagon-like peptide-1 (GLP-1).31 Several GLP-1 receptor 
agonists are currently available for the treatment of type 2 dia-
betes mellitus and are classified as short-acting with a dura-
tion of action of only a few hours after subcutaneous (s.c.) 
injections, and long-acting GLP-1 receptor agonists able to 
maintain plasma levels through the day (Table 1).32,33 For 
instance, due to the dipeptidyl peptidase-4 (DPP-4) degrada-
tion of incretins, a group of GLP-1 agonists resistant to deg-
radation by DPP-4 has been developed such as sitagliptin, 
vildagliptin, saxagliptin, and linagliptin.34 In patients with 
type 2 diabetes and CVD, multiple drugs from this group have 
shown a lower rate of cardiovascular disease outcomes such as 
cardiovascular death, nonfatal myocardial infarction, 
STUDy How HyPoGlyCEMiA wAS DEFiNED iN THE 
STUDy
Gough et al17 Hypoglycemia was defined as the occurrence 
of episodes requiring assistance (severe), or 
episodes in which plasma glucose 
concentration (determined from self-monitored 
glucose) was less than 3.1 mmol/l (56 mg/dl), 
irrespective of symptoms.
wysham et al18 Symptomatic hypoglycaemia with plasma 
glucose ⩽3.9 mmol/l (⩽70 mg/dl)
Vilsbøll et al19 Plasma glucose at or below 2.5 mmol/l
Buse et al20 Major hypoglycaemic episodes were defined 
as requiring third-party assistance with food 
only, glucagon, or intravenous glucose. Minor 
episodes were defined as those that the 
participant could self-treat and for which the 
plasma glucose concentration was less than 
3.1 mmol/l. At glucose concentrations of 
3.1 mmol/l or more, or in the absence of 
glucose measurements, episodes were 
regarded as symptoms only
Knop et al21 Symptoms of hypoglycemia, and biochemical 
hypoglycemia (with PG concentrations 
⩽2.5 mmol/l)
Miholic et al22 Hypoglycemia (ie, serum glucose <3.8 mmol/l) 
after the test meal
Blevins et al23 Hypoglycemic episodes were classified as 
major or minor. Major hypoglycemia was 
defined as events that resulted in loss of 
consciousness, seizure, coma, or other 
change in mental status consistent with 
neuroglycopenia, in which symptoms resolved 
after administration of intramuscular glucagon 
or iV glucose. Hypoglycemia requiring 
assistance because of severe impairment in 
consciousness or behavior accompanied by a 
blood glucose concentration less than 54 mg/dl 
(3.0 mmol/l) before treatment was also 
classified as major. Minor hypoglycemia was 
defined as events with symptoms consistent 
with hypoglycemia accompanied by a blood 
glucose concentration less than 54 mg/dl 
(3.0 mmol/l) before treatment
Ratner et al24 Symptomatic hypoglycaemia was defined as 
symptoms consistent with hypoglycemia, with 
an accompanying blood glucose <3.3 mmol/l 
or prompt recovery with carbohydrate.
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or nonfatal stroke when compared to placebo. For instance, 
liraglutide,35 dulaglutide,36 and semaglutide35 reduced the risk 
of cardiovascular events. However, different side effects have 
been reported in treated patients, including gastrointestinal 
effects such as nausea, diarrhea, vomiting, constipation, 
abdominal pain, and dyspepsia.37 In addition, pancreatitis and 
progression to pancreatic cancer have been suggested to be 
associated with GLP-1 agonist treatments. A recent study 
reported that incretin therapy is not associated with an 
increased risk of pancreatic cancer in animals.38 As well, 
metaanalyses studies supports the lack of association of GLP-1 
with pancreatic cancer.39 However, another study showed 
GLP-1 receptor agonists’ effect on the β-cell mass in animal 
models where GLP-1 acted as a β-cell growth factor leading 
to increased insulin synthesis and β-cell mass40; those results 
however have not been replicated in humans. Additionally, 
medullary thyroid cancer was reported in rodents when 
exposed to GLP-1 receptor agonists but not in primates.37,38
Table 2 summarizes different types of available GLP-1 
receptor agonists used alone or combined with other drugs. 
Figure 1. Schematic of action of GlP-1 on insulin secretion.
Figure 2. Schematic of proposed mechanism of hypoglycemia in GlP-1 receptor agonists.
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Table 2. Summary of the literature that described the hypoglycemic effect of GlP1 receptor agonists.
STUDy GlP-RECEPToR 
AGoNiST USED




Edwards et al11 Subcutaneous GlP-1 — 10 healthy subjects 10%
lerche et al12 Continuous infused 
native GlP-1
— 8 healthy men 37.5%
Nauck, M., et al14 once daily liraglutide in 
combination with 
metformin
Glimepiride + metformin or 
placebo + metformin
1091 subjects previously 
treated with oral 
antidiabetic (oAD) therapy.
∼3% of subjects in the placebo 
and liraglutide groups and 17% 
in the glimepiride group
Marre et al15 liraglutide + glimepiride Rosiglitazone + glimepiride
Placebo + glimepiride
1041 adults with type 2 
diabetes mellitus
<10% of subjects for any 
treatment glimepiride 
monotherapy 2.6%, -liraglutide 
0.6 mg 5.2%, rosiglitazone 4.3%
Nauck et al2 iV GlP-1 Regular insulin Nine healthy volunteers 
with normal oral glucose 
tolerance
N/A
Buse et al20 liraglutide once a day or 
exenatide twice a day in 
addition to their previous 
oral antidiabetic therapy.
Metformin or A 
sulphonylurea
Adults with inadequately 
controlled type 2 
diabetes on maximally 
tolerated doses of 
metformin, 
sulphonylurea, or both
Minor hypoglycemia: 26% with 
liraglutide vs 34% with 
exenatide
Blevins et al23 Exenatide once weekly 
and exenatide twice 
daily
— 252 intent-to-treat 
patients with type 2 
diabetes
Minor hypoglycemia occurred 
only among subjects using a 
concomitant sulphonylurea 
6.75% in the exenatide once 
weekly with a SU 
(sulphonylurea) group 5.4% in 
the exenatide twice daily with a 
SU group
Ratner et al24 Subcutaneous 
lixisenatide




Vilsbøll et al19 Subcutaneous injection 
of GlP-1 plus iV glucose 
bolus
— Eight Type 2 diabetic 
patients and 7 non-
diabetic subjects
71% of the healthy subjects but 
none of the subjects with type 
2 diabetes
Knop et al21 Subcutaneous injection 
of GlP-1 plus iV glucose 
bolus
— Eight lean type 2 diabetic 
patients and 8 patients 
with type 2 diabetes 
secondary to chronic 
pancreatitis
Neither symptoms of 
hypoglycemia nor biochemical 
hypoglycemia were observed 
in any patient
Gough et al17 A fixed-ratio 
combination of insulin 
degludec and liraglutide 
(iDeglira)
insulin degludec alone 
liraglutide alone
1663 adults with type 2 
diabetes
Number of confirmed 
hypoglycaemic events per 
patient year was 1.8 for 
iDeglira, 0.2 for liraglutide, 
and 2.6 for insulin degludec
Table 1. Commercially available GlP-1 agonists.
SHoRT-ACTiNG loNG-ACTiNG
Exenatide (twice daily within 60 min prior to morning and evening meals) Exenatide-lAR (once weekly)
lixisenatide (once daily) liraglutide (once daily)
oral semaglutide (taken by mouth once daily) Albiglutide (once weekly)
 Dulaglutide (once weekly)
 Semaglutide (once weekly)
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Edwards et  al concluded that hypoglycemia can be observed 
following infusion of subcutaneous GLP-1, however, the study 
was limited to 10 healthy subjects.
On the other hand, the other studies reported hypoglycemic 
phenotype when GLP-1 agonists were given alongside other 
drugs such as sulphonylureas and the only other instance of 
hypoglycemia was observed in healthy subjects injected with 
GLP-1 but not type 2 diabetic patients, potentially due to their 
impaired insulin sensitivity and insulin resistance.
Since their discovery, GLP-1 receptor agonists have been 
considered a good treatment option mainly because of their 
favorable effect on glycemic control, which can sometimes be 
challenging to achieve. They have also been the right choice for 
people who cannot tolerate metformin or cannot use insulin 
because of its weight gaining side effects.41 Glucagon-like pep-
tide 1 (GLP-1)-based therapies (GLP-1 receptor agonists, 
dipeptidyl peptidase 4 inhibitors); a class of drugs with none of 
the adverse effects commonly seen in insulin and oral sulpho-
nylureas seemed like the superior option.
However, the possibility of hypoglycemia was raised in 
different reports. For instance, in 1998 a double-blind, ran-
domized study of 10 healthy subjects injected with GLP-1 
or saline subcutaneously after a 16-hour fast was performed 
and argued that a GLP-1 injection could cause hypoglyce-
mia in healthy subjects who did not have hyperglycemia. 
Interestingly, the results showed that GLP-1 receptor ago-
nists acted as insulinotropic in a glucose-independent man-
ner.11 On the other hand, a randomized double-blind 
placebo-controlled study was conducted including 8 healthy 
men to assess the safety, in terms of hypoglycemia, of a con-
tinuously infused pharmacological dose of native GLP-1 
during long-term fasting. The results showed that plasma 
glucose levels were similar during GLP-1 versus placebo 
infusions, and therefore, it was concluded the use of long-
acting GLP-1 receptor agonists might not cause hypoglyce-
mia.12 Many similar reports followed, which all confirmed 
that GLP-1 receptor agonists could cause only minor and 
non-significant hypoglycemic events, and even those 
occurred at a low rate. In 2009, Nauck et  al assessed the 
efficacy and safety of adding liraglutide to metformin com-
pared with placebo or glimepiride to metformin in subjects 
previously treated with oral antidiabetes (OAD) therapy. 
One thousand ninety-one subjects with type 2 diabetes were 
randomly assigned to once-daily liraglutide, placebo, or 
glimepiride. All treatments were given in combination with 
metformin. At the end of the 26-week study, it was observed 
that the incidence of minor hypoglycemia with liraglutide 
was comparable to that with placebo but less than that with 
glimepiride. However, no major hypoglycemic events were 
reported.14 In addition, some cases of GLP-1 overdoses 
were reported in accidental occasions, however, the overdose 
of GLP-1 receptor agonist did not show an impact on hypo-
glycemia development.10
Additionally, GLP-1 therapy may be beneficial in elderly 
but then discourages use in this cohort. There is potential that 
GLP-1 therapy may benefit comorbidities and preclinical data 
on memory and dementia may be translatable to humans. 
Polypharmacy, which is frequently observed in the elderly, 
increases risk of drug—drug and drug—disease interactions 
and therefore using 1 medication (the GLP-1 receptor agonist) 
may help reduce the burden of polypharmacy, medication cost, 
and medication non-adherence. However, the elderly have a 
higher risk of adverse drug effects, including hypoglycemia due 
to polypharmacy, age-related changes affecting drug metabo-
lism, and non-adherence to medication.42
Is the hypoglycemia related to additional risk 
factors?
It can be argued that the possible hypoglycemic effect is due to 
concomitant use of other therapies that cause hypoglycemia 
(eg, sulphonylurea) and it was demonstrated in clinical trials 
studying a combination of a GLP-1 receptor agonist and a 
sulphonylurea that the risk of hypoglycemia was higher when 
compared to placebo.15 The hypoglycemic effect has been 
attributed to the uncoupling of GLP-1 from its glucose 
dependence by the Sulphonylurea.43 A clinical trial in 2002 
concluded that the suppression of glucagon by GLP-1 occurs 
at euglycemia.16 Additionally, the hypoglycemic effect of 
GLP-1 receptor agonists was attributed to the suppression of 
glucagon secretion. In another study, a case report of a 54-year-
old Caucasian female with type 2 diabetes treated with a 3 
drugs regimen, 1 of which was a GLP-1 agonist (Liraglutide) 
after which she experienced confusion and an episode of hypo-
glycemia for which she was hospitalized and found to have a 
pancreatic mass that was confirmed to be a benign insulinoma. 
Interestingly, the benign insulinomas overexpressed GLP-1 
receptors and the administration of a GLP-1 agonist provoked 
this hypoglycemia. Therefore the case report concluded that an 
insulinoma should be considered when a patient develops 
severe hypoglycemia on a GLP-1 agonist.44
The combination of insulin and a GLP-receptor 
agonist
A clinical trial published in The Lancet in 2014 compared the 
efficacy and safety of a fixed-ratio combination of insulin 
degludec and liraglutide (IDegLira) compared with its compo-
nents given alone. In the 26-week open-label, randomized trial, 
adults with type 2 diabetes were randomly assigned to daily 
injections of IDegLira, insulin degludec, or liraglutide. The 
number of confirmed hypoglycemic events per patient-year 
was 1.8 for IDegLira, 0.2 for liraglutide, and 2.6 for insulin 
degludec, confirming the assumption that a combination of 
insulin and a GLP-1 receptor agonist would have a higher risk 
of hypoglycemia.17 The LixiLan-L trial evaluated 736 patients 
with type 2 diabetes mellitus inadequately controlled on basal 
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insulin alone or in combination with 1 or 2 glucose-lowering 
drugs. Patients treated with iGlarLixi (insulin glargine/lixi-
senatide titratable fixed-ratio combination) showed greater 
reductions in HbA1c and no major differences in hypoglyce-
mia incidence than patients treated with insulin glargine.18
Interestingly, it was demonstrated that subcutaneous GLP-1 
plus intravenous-glucose induced reactive hypoglycemia in 
healthy subjects, but not in Type 2 diabetic patients. The study 
included 8 patients with type 2 diabetes and 7 non-diabetic 
subjects were given a subcutaneous injection of GLP-1 and an 
intravenous injection of glucose; hypoglycemia was observed in 
5 of the 7 healthy subjects but none the patients with diabetes 
therefore it was concluded that hypoglycemia shouldn’t be 
expected in patients with type 2 diabetes treated with GLP-1 
based therapies.19 The possible proposed reason for the absence 
of hypoglycemia is the impaired insulin response and increased 
insulin resistance in those with type 2 diabetes. Therefore, it 
was also essential to investigate diabetic patients with normal 
or close to normal insulin sensitivity. Another study supported 
this assumption that included 8 lean type 2 diabetic patients 
and 8 patients with type 2 diabetes secondary to chronic pan-
creatitis. All patients were given a subcutaneous injection of 
GLP-1 and an intravenous glucose bolus. Both groups showed 
impaired insulin secretory capacity and close to normal insulin 
sensitivity without hypoglycemic impact. Therefore, it was 
concluded that GLP-1 receptor agonists based therapy could 
not cause hypoglycemia even in insulin-sensitive type 2 dia-
betic patients.21
Bariatric surgery and hypoglycemia
Dumping syndrome occurs when food moves from the stom-
ach into the duodenum too quickly. The food passage stimu-
lates the release of gut hormones, and water shifts from the 
bloodstream into the intestines leading to bloating, diarrhea, 
hypotension, tachycardia, and reactive hypoglycemia due to the 
exaggerated release of insulin. This phenomenon occurs mostly 
following different types of bariatric surgery, such as sleeve gas-
trectomy and Roux-en-Y gastric bypass. It has been proposed 
that GLP-1 may contribute to the exaggerated insulin surge 
and resultant hypoglycemia. This hypothesis is supported after 
reporting exaggerated GLP-1 secretion and hypoglycemia in 
patients who underwent gastrectomy.22,45 So patients with 
rapid gastric emptying may have an exaggerated response to 
GLP-1 receptor agonists.
Do different GLP-1 receptor agonists have 
different risks of hypoglycemia?
In a randomized control trial that included adults with inade-
quately controlled type 2 diabetes on maximally tolerated doses 
of metformin, sulphonylurea, or both, the participants were 
randomly assigned additional liraglutide once a day or exena-
tide twice a day and it was demonstrated that minor 
hypoglycemia was less frequent with liraglutide than with 
exenatide.20 A meta-analysis study showed that long and short-
acting agonists had different rates of hypoglycemia occurrence. 
For instance, randomized controlled trials comparing the coad-
ministration of short- or long-acting GLP-1 RAs and basal 
insulin with basal insulin ± placebo were identified, and data 
about differences in HbA1c, fasting plasma glucose, body 
weight, and adverse events were extracted. Hypoglycemia as a 
side effect occurred more frequently in patients treated with 
GLP-1 RAs and basal insulin than in those treated with basal 
insulin ± placebo. Patients reporting symptomatic but not 
severe hypoglycemia were fewer with long- versus short-acting 
GLP-1 RAs added to insulin.46 Those results were supported 
by another randomized control study that compared the effects 
of exenatide once weekly and exenatide twice daily and reported 
no major hypoglycemic events at all.23
Short-acting agonists were evaluated in several studies as 
well. For instance, Lixisenatide was evaluated for safety, effi-
cacy, and adverse events in a randomized, double-blind, pla-
cebo-controlled, parallel-group, 13-week study of 542 patients 
with Type 2 diabetes inadequately controlled on metformin 
(⩾1000 mg/day) treated with subcutaneous lixisenatide doses 
of 5, 10, 20, or 30 μg once daily or twice daily or placebo. In 
terms of hypoglycemia, a dose relationship between sympto-
matic hypoglycaemic episodes and severe hypoglycemia was 
not observed at all.24
GLP-1 receptor agonists and other adverse effects
Gastrointestinal adverse effects. Nausea, vomiting, and diar-
rhea are the most commonly shown side effects of GLP-1 ago-
nists. In addition, this class of drugs increases satiety which may 
cause temporary and mild nausea if taken on a rather full stom-
ach. Pruritus and erythema at the injection site are also prevalent, 
particularly with the longer-acting drugs in this class.47 There 
was less incidence of nausea for exenatide once weekly than with 
twice-daily exenatide or liraglutide. In comparison with exena-
tide twice daily, lixisenatide also showed decreased rates of nau-
sea. Albiglutide had lower rates of nausea than liraglutide among 
the 2 most recently approved GLP-1RAs, whereas dulaglutide 
had similar rates compared to liraglutide; however, taspoglu-
tide (long-acting glucagon-like peptide 1 receptor agonist) had 
by far the highest rates of nausea: 53% and 59% with 10 and 
20 mg once weekly, respectively, compared with 35% among par-
ticipants treated with exenatide twice daily. This was one of the 
key reasons why taspoglutide clinical research was stopped.48. In 
general, it was found that a less frequent weekly dose is more 
beneficial in terms of gastrointestinal compliance for the patents 
in comparison to the daily dose regimens.49.
It is also worth mentioning that albiglutide was discontinued in 
2017 due to limited prescribing of the drug and declining sales.50
Pancreatitis. Concerns about the potential relationship 
between GLP-1 receptor agonist therapy and pancreatic 
inflammation and pancreatitis have been introduced. In this 
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aspect, animal research has demonstrated that these medica-
tions have a potentially adverse effect on pancreatic tissue, 
ranging from chronic pancreatic damage to lab animals, char-
acterized by acinar cell pyknosis, increased cytoplasmic vacu-
oles, expanded cell distance, till pancreatic tissue inflammatory 
cell infiltration.51,52 The concern was augmented, causing the 
US Food and Drug Administration (FDA) to investigate the 
risk of pancreatitis associated with the use of incretin agonist 
drugs. In one of them, the usage of incretin-mimetic thera-
pies was assessed for 30 days to 2 years, which is correlated 
with an elevated risk of acute pancreatitis relative to non-users. 
A combined review of phase III clinical tests and 2 outcome 
analyses revealed a marginally greater (but not significant) risk 
of GLP-1 receptor agonist pancreatitis relative to alternative 
treatment results.53
On the other hand, most recent trials and meta-analyses 
have failed to demonstrate an elevated risk of pancreatitis.54,55 
Also, compared to controls, a more recent meta-analysis of 55 
randomized clinical trials found no elevated risk of pancreati-
tis with GLP-1 agonists.56 Similarly, no critical link between 
incretin-based therapy and acute pancreatitis was observed in 
another recent meta-analysis of 9 observational trials.57 
Moreover, more than 250 toxicology tests and more than 200 
studies have recently been re-evaluated by the FDA and the 
European Medicines Agency (EMA) in a collaborative review; 
both agencies agreed that the concerns raised by many writers 
and the media concerning a potential causal interaction of 
incretin-mimetic drugs with acute pancreatitis are inconsist-
ent with the concerns expressed by many authors and the 
media.58 No clear cause-and-effect association between 
GLP-1 receptor agonists and pancreatitis has been shown, but 
before this issue is eventually settled, it may be advisable not to 
prescribe GLP-1 receptor agonists to patients with many pan-
creatitis risk factors, such as extreme hypertriglyceridemia or 
alcohol consumption.59
Cardiovascular effect. It has been shown that GLP-1 recep-
tor agonists decrease systolic blood pressure (SBP) and to a 
lesser degree, diastolic blood pressure (DBP). GLP-1 recep-
tor agonists were associated with substantial decreases in SBP 
for dulaglutide and albiglutide relative to placebo in a network 
meta-analysis of 60 clinical trials. A marked decrease in DBP 
compared to placebo was found for exenatide only.60 Another 
favorable outcome during therapy with GLP-1 receptor ago-
nists was that a decrease in lipid levels has also been noted. A 
35 clinical trial network meta-analysis found that these com-
pounds were associated with substantial declines in LDL cho-
lesterol and total cholesterol versus control.61
The safety of incretin-based drugs in heart failure has been 
addressed in several studies. A study in 2016 examined existing 
data from multiple cohorts of patients to determine whether 
the use of incretin-based drugs, as compared with oral antidia-
betic-drug combinations, in routine clinical practice is associ-
ated with an increased risk of heart failure and they found that 
it was not associated with an increased risk of hospitalization 
for heart failure.62 Another study that evaluated clinical out-
comes in patients with diabetes, treated by cardiac resynchroni-
zation therapy with a defibrillator (CRT-d), and glucagon-like 
peptide 1 receptor agonists (GLP-1 RA) in addition to con-
ventional hypoglycemic therapy versus CRTd patients under 
conventional hypoglycemic drugs found that CRTd patients 
with diabetes treated by GLP-1 RA therapy versus CRTd 
patients with diabetes that did not receive GLP-1 RA therapy, 
experienced a significant reduction of NYHA class, associated 
to higher values of 6 minutes walking, and higher rate of CRTd 
responders. CRTd responders were defined as HFrEF patients 
with diabetes who received cardiac resynchronization therapy 
with a defibrillator (CRT-d) treatment and displayed improved 
cardiac performance and functional New York Association 
Heart (NYHA) class, and a reduction in hospital admissions 
and mortality. GLP-1 RA patients versus controls at follow up 
end experienced lower AF events (P value <0.05), lower VT 
events (P value <0.05), lower rate of hospitalization for heart 
failure worsening (P value <0.05), and higher rate of CRTd 
responders (P value <0.05), therefore, GLP-1 RA therapy 
added to conventional hypoglycemic therapy may play a pro-
tective role against arrythmias in HFrEF patients who receive 
CRTd therapy.63
SIRT6 is a gene that encodes a member of the sirtuin family 
of NAD-dependent enzymes that are implicated in cellular 
stress resistance, genomic stability, aging, and energy homeo-
stasis. The encoded protein is localized to the nucleus, exhibits 
ADP-ribosyl transferase and histone deacetylase activities, and 
plays a role in DNA repair, maintenance of telomeric chroma-
tin, inflammation, lipid, and glucose metabolism.64 A study 
from 2015 hypothesized that, by acting on SIRT6, diabetes 
may enhance the inflammatory potential of atherosclerotic 
plaques, favoring their instability, and evaluated the effect of 
incretin therapy in diabetic patients on SIRT6 expression in 
carotid plaques and early outgrown circulating endothelial pro-
genitor cells (EPCs), it found that compared with nondiabetic 
plaques, diabetic plaques had more inflammation and oxidative 
stress, along with a lesser SIRT6 expression and collagen con-
tent. Compared with non-GLP-1 therapy-treated plaques, 
GLP-1 therapy-treated plaques presented greater SIRT6 
expression and collagen content, and less inflammation and 
oxidative stress, indicating a more stable plaque phenotype.65
In addition, incretin-based therapies have shown benefits in 
patients with NSTEMI-NOCS (non-obstructive coronary 
artery stenosis [NOCS]––Non-ST-Elevation Myocardial 
Infarction [NSTEMI]). A recent study from 2017 investigated 
the 12-months prognosis in the cohort of NSTEMI-NOCS 
diabetics, previously treated by incretin-based therapy, com-
pared with a matched cohort of NSTEMI-NOCS diabetics 
never treated with such therapy and results showed that 1-year 
mortality and adverse cardiovascular outcomes were higher in 
patients with NOCS-NSTEMI and type 2 diabetes mellitus as 
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opposed to patients with NOCS-NSTEMI alone. Also dia-
betic never-incretin-users had a worse prognosis as compared 
to diabetic current-incretin-users (6 months, GLP-1 agonists 
or DPP-4 inhibitors).66 In STEMI, type 2 diabetic patients 
with STEMI-Mv-NOCS (multivessel non obstructive coro-
nary stenosis), showed a higher incidence of 1-year mortality 
and adverse cardiovascular outcomes, as compared to non-dia-
betic STEMI-Mv-NOCS patients. And again, in diabetic 
patients, never-incretin-users had a worse prognosis as com-
pared to current-incretin-users.67
The available data do not indicate any increase in severe 
cardiovascular adverse events with GLP-1 receptor agonists.68 
However, administration of the GLP-1 receptor agonist has 
been linked with a minor rise in heart rate. A meta-analysis of 
22 experiments found that GLP-1 agonists resulted in a sig-
nificant increase in heart rate compared with placebo, with a 
weighted mean difference of 1.86 beats per minute (bpm) and 
1.90 bpm compared with active control. Daily and weekly 
doses, in addition to short or long-acting GLP-1 agonists, 
slightly affected the overall outcome of tachycardia.69 Whereas 
in general, the increase in heart rate with GLP-1 receptor ago-
nists is minimal but remains clinically relevant as heart rate is a 
marker of cardiovascular adverse effects.70
In contrast, DPP-4 inhibitors have not shown similar posi-
tive effects on cardiovascular outcomes. Based on currently 
available evidence DPP-4 inhibitors show only a neutral effect 
on cardiovascular outcomes in patients with high risk or estab-
lished CVD in diabetes.71
Allergy and angioedema. Due to the nature of their route 
of administration, as subcutaneously injected peptides, and 
the different immunogenic properties between the class 
members, hypersensitivity, and immunological reactions 
were anticipated with the concomitant use. The occurrence 
of immune-related and hypersensitivity reactions was dem-
onstrated following re-exposure to exenatide was evaluated 
in 58 T2D patients in a multicenter, open-label, 24-week 
trial. Treatment-emergent adverse effects were observed in 
40% and 47% of patients with positive and negative treat-
ment-emergent antibodies, respectively.72 Further studies 
on exenatide, found that in the small subset of patients with 
higher antibody titers (5%), the decrease in HbA1c was not 
significantly reduced twice-daily with exenatide. In addition, 
a significant decrease in efficacy was observed in the subset 
of patients who received exenatide once weekly and who 
had high antibody titers (12%). These findings represent a 
clinically relevant finding that exenatide decreases exenatide 
efficacy in patients who develop high titers of emergent treat-
ment antibodies.73 Severe anaphylactic reactions have not 
been reported with GLP-1 receptor agonists. However, post-
marketing reports showed that anaphylactic reactions rarely 
occur with liraglutide, exenatide very rarely, and lixisenatide 
uncommonly. In addition, rare post-marketing reports of 
exenatide, liraglutide, and lixisenatide have been described for 
pruritus, urticaria, and angioneurotic edema.74-77
Injection-site reactions. Because of variations in recording 
outcomes methods, it is difficult to compare injection site reac-
tions between experiments. Overall, GLP-1RAs once a week 
tend to be linked with higher incidences of an injection-site 
reaction than twice-daily exenatide or once-daily liraglutide. In 
the HARMONY-7 trial, for example, injection site reactions 
with albiglutide (13%) occurred more often than with liraglu-
tide.78 In the DURATION trial, a similar finding was made in 
which patients administered with exenatide once weekly than 
liraglutide reported higher incidences of nodules at the injec-
tion, pruritus at the injection site, and erythema at the injec-
tion site. Higher rates of injection site reactions reported in 
these studies are consistent with outcomes observed with other 
injectable drug formulations.79 Exenatide and albiglutide have 
the highest incidence of skin reaction compared to lixisena-
tide having the least.76,77,80 Reactions at the injection site are 
recorded more often with long-acting receptor agonists than 
with short-acting GLP-1 receptor agonists. Pruritus in the 
primary injecting site reaction is the most prominent. These 
reactions are more commonly temporary and do not usually 
require medication to be stopped. Interestingly, patients receiv-
ing GLP-1 receptor analogs and producing anti-drug anti-
bodies appear to have more injection site reactions because 
patients who do not produce antibodies experience comparable 
frequency and forms of adverse effects to those experienced.81
Conclusions
Up to date, there is no clear evidence supporting the probabil-
ity of sole GLP-1 agonist-induced hypoglycemia. GLP-1 
receptor agonists have shown effective outcomes of glycemic 
control in type 2 diabetic patients especially in the elderly 
patients who are already taking other drugs for different con-
ditions. GLP-1 receptor agonists have not been linked to 
weight gain and the possible risk of hypoglycemia has not 
been demonstrated. Our review suggests that hypoglycemia 
cannot occur in type 2 diabetic patients because of their insu-
lin resistance and impaired insulin response. However, 1 clini-
cal trial,11 reported 3 instances of hypoglycemia out of 10 
healthy patients.
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